Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2000

View Archived Issues

NIAID awards grants for drug and vaccine development

Epicyte receives grants for sexual health applications

Advanced Biotherapy's anti-interferon gamma drug shows promise in the clinic

Clinical trial results for IL-2/SEB combination therapy for melanoma positive

PI-88's novel mechanism of action revealed; compound enters two new trials

NIDA grant awarded to Nabi for nicotine vaccine research

Myriad reports location of prostate cancer susceptibility gene

AxyS selects lead compound in asthma program

Ertapenem displays activity against a wide range of anaerobes causing intraabdominal infection

Salus receives SBIR grant for cystic fibrosis research

FDA approves first and only once-monthly contraceptive for women

Periostat now available in the U.K., its first European market

Coulter's Bexxar assigned priority review status by FDA

Parke-Davis reports SAR investigations on novel non-nucleoside antiviral agents

Initial evaluation of female sexual response using MS-325

Positive effects of PARP inhibitor in animal model of acute inflammation

Preclinical data support clinical trials of repifermin in ulcerative colitis

Marine natural product shows promise for hyperproliferative and inflammatory conditions

CRL-8256, with potential in cancer chemotherapy, emerges from joint French and Belgian research

Favorable ML-3000 clinical data presented during OARSI congress

Numerous lead compounds emerge from Versicor's oxazolidinone combinatorial libraries

Sulfonamides designed by two major labs as potential Alzheimer's disease therapies

NOS inhibitors in the Pfizer pipeline reported in patent literature

Novel target for anticancer therapy and new compounds discovered at Klinge

Roche's new NK1 receptor antagonists intended particularly for depression and emesis

New PDE4 inhibitors and methods of treating asthma

Boehringer Ingelheim identifies new series of cytokine-inhibitory antiinflammatory agents

International patent coverage obtained for new thrombin inhibitors from Boehringer Ingelheim

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...